Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

3 terminated/withdrawn out of 15 trials

Success Rate

72.7%

-13.9% vs industry average

Late-Stage Pipeline

33%

5 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

8(53.3%)

Phase 3

5(33.3%)

Phase 1

1(6.7%)

N/A

1(6.7%)

15Total

Phase 2(8)

Phase 3(5)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT05611931Phase 3Active Not Recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Role: collaborator

NCT03786081Phase 1Terminated

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Role: collaborator

NCT05581121Phase 3Recruiting

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

Role: collaborator

NCT03555422Phase 3Completed

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

Role: collaborator

NCT01244789Phase 2Active Not Recruiting

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Role: collaborator

NCT04742075Phase 2Active Not Recruiting

Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer

Role: collaborator

NCT02730416Phase 2Completed

Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer

Role: collaborator

NCT01658930Not ApplicableCompleted

Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

Role: collaborator

NCT03598270Phase 3Completed

Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

Role: collaborator

NCT02009579Phase 2Completed

ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer

Role: lead

NCT05201001Phase 2Withdrawn

APX005M in Patients With Recurrent Ovarian Cancer

Role: collaborator

NCT03438396Phase 2Completed

A Trial of Tisotumab Vedotin in Cervical Cancer

Role: collaborator

NCT02477644Phase 3Completed

Platine, Avastin and OLAparib in 1st Line

Role: collaborator

NCT03795272Phase 2Withdrawn

Rucaparib Maintenance Therapy in Advanced Cervical Cancer

Role: collaborator

NCT01523678Phase 2Completed

Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers

Role: lead

All 15 trials loaded